At the time of writing, Travere Therapeutics Inc [TVTX] stock is trading at $16.41, down -4.09%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TVTX shares have gain 7.75% over the last week, with a monthly amount glided 30.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on September 09, 2024, when Guggenheim upgraded its rating to a Buy but kept the price target unchanged to $25 for it. Previously, Guggenheim downgraded its rating to Neutral on March 27, 2024. On December 05, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. Citigroup started tracking the stock assigning a Neutral rating and suggested a price target of $7 on November 20, 2023. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $8 on September 22, 2023. William Blair downgraded its rating to Mkt Perform for this stock on September 21, 2023.
For the past year, the stock price of Travere Therapeutics Inc fluctuated between $5.12 and $18.60. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $16.41 at the most recent close of the market. An investor can expect a potential return of 31.02% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
According to Travere Therapeutics Inc [NASDAQ:TVTX], the company’s sales were 177.64M for trailing twelve months, which represents an -9.35% plunge. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -2.13%, Pretax Profit Margin comes in at -2.16%, and Net Profit Margin reading is -0.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -1.02 and Total Capital is -0.88. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of25.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.84 points at the first support level, and at 15.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.49, and for the 2nd resistance point, it is at 18.57.
Ratios To Look Out For
It is important to note that Travere Therapeutics Inc [NASDAQ:TVTX] has a current ratio of 3.04. Further, the Quick Ratio stands at 2.99, while the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 7.07, the price to book ratio is 82.83.
Transactions by insiders
Recent insider trading involved LYONS GARY A, Director, that happened on Oct 04 ’24 when 40000.0 shares were sold. Officer, GARY A LYONS completed a deal on Oct 04 ’24 to buy 40000.0 shares. Meanwhile, Director Meckler Jeffrey A sold 40000.0 shares on Sep 30 ’24.
